Assessment of the efficacy of reducing peginterferon alfa-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C

Korean Journal of Internal Medicine

Volumn 24, Issue 3, 2009, Pages 203-211

  Kwon, Jung Hyun ^a   Bae, Si Hyun ^a   Choi, Jong Young ^a   Yoon, Seung Kew ^a   Byun, Kwan Soo ^b   Paik, Seung Woon ^c   Lim, Young Suk ^d   Lee, Han Chu ^d   Han, Kwang Hyub ^e   Lee, Kwan Sik ^e  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

Hepatitis C; Koreans; Peginterferon alfa 2a; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BODY WEIGHT; CHRONIC HEPATITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; KOREA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PRURITUS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; AGED; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; MULTICENTER STUDY; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL;

EID: 70449711352     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2009.24.3.203     Document Type: Article

References (21)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965. (Pubitemid 32913521)
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
3. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
4. Lee H, Choi MS, Paik SW, et al. Peginterferon α-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea. Korean J Hepatol 2006;12:31-40.
5. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003;124:1711-1719. (Pubitemid 36617688)
6. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-2451.
7. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002;36(5 Suppl 1):S237-S244. (Pubitemid 35253486)
8. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1- infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.
9. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652. (Pubitemid 37052151)
10. Lamb MW, Martin NE. Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a. Ann Pharmacother 2002;36:933-935.
11. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-379. (Pubitemid 47344771)
12. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006;43:54-63. (Pubitemid 43733592)
13. Yu ML, Dai CY, Lin ZY, et al. A randomized trial of 24- vs. 48- week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006;26:73-81.
14. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-1023. (Pubitemid 38451173)
15. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007;132:103-112. (Pubitemid 46127673)
16. Meyer-Wyss B, Rich P, Egger H, et al. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat 2006;13:457-465. (Pubitemid 43911755)
17. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000;32:647-653. (Pubitemid 30676928)
18. Camps J, García N, Riezu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993;19:408-412. (Pubitemid 24029918)
19. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995;23(Suppl 2):8-12. (Pubitemid 26048737)
20. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-527. (Pubitemid 41096640)
21. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-134. (Pubitemid 47057730)